Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01225770
Other study ID # CT2010001
Secondary ID
Status Recruiting
Phase Phase 3
First received October 19, 2010
Last updated February 12, 2013
Start date November 2010
Est. completion date August 2014

Study information

Verified date February 2013
Source University of Shizuoka
Contact Hiroshi Yamada, MD, PhD
Phone +81-54-264-5762
Email hyamada@u-shizuoka-ken.ac.jp
Is FDA regulated No
Health authority Japan: Ministry of Health, Labor and Welfare
Study type Interventional

Clinical Trial Summary

Experimental and clinical studies in adults have reported that green tea catechins prevent influenza infection. In this clinical randomized study, the investigators aimed to determine the effects of gargling with green tea on the prophylaxis of influenza infection among high school teenagers.


Description:

Influenza infection is the principal cause of acute respiratory illnesses and occurs in epidemic or pandemic worldwide. It spreads easily among high school students and from them to the rest of the community; therefore the prevention of influenza is very important.

Experimental studies have revealed that some components of green tea can prevent influenza infection in vitro. In clinically, gargling with green tea catechins has been reported to have possibilities to preventing influenza infection in adults; however, little clinical evidence in teenagers has so far been existed. Based on this background, the investigators designed a randomized study to evaluate the clinical efficacy of gargling with green tea in preventing influenza infection among high school students.


Recruitment information / eligibility

Status Recruiting
Enrollment 640
Est. completion date August 2014
Est. primary completion date April 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 15 Years to 20 Years
Eligibility Inclusion Criteria:

- aged from 15 to 20 years

- obtained written informed consent from both the student and parent before participation

- possible to gargle during 90 days

- possible to fill in questionnaire

Exclusion Criteria:

- Possessing allergy to green tea

- Possessing history of influenza infection within 6 months before entering the study

- Possessing severe immune disease or whole body infection

- severe cardiac, respiratory, renal, or hepatic dysfunction

- diagnosed as inadequate to participate in the study by student doctor

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Intervention

Dietary Supplement:
green tea
Gargling three times daily for 90 days

Locations

Country Name City State
Japan University of Shizuoka Shizuoka

Sponsors (1)

Lead Sponsor Collaborator
University of Shizuoka

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary the incidence rates of influenza infection Until 3 months gargling No
Secondary severity of influenza symptoms until 3 months gargling No
Secondary influenza-free time during the study period until 3 months gargling No
Secondary incidence of complications until 3 months gargling No
Secondary incidence rates of upper respiratory tract infections until 3 months gargling No
Secondary incidence of days of absence from school until 3 months gargling No
Secondary occurrence of the adverse events until 3 months gargling Yes
See also
  Status Clinical Trial Phase
Completed NCT00603811 - Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults Phase 1
Completed NCT03784885 - A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult Phase 2
Recruiting NCT05436444 - Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model Phase 1
Completed NCT01201902 - A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine Phase 3
Completed NCT00559975 - Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine Phase 1
Terminated NCT00647465 - Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer Phase 3
Completed NCT01008020 - Effects of Tea Catechin Consumption on the Prophylaxis of Influenza Infection N/A
Completed NCT00239213 - Catechin Gargling for Influenza Infection N/A
Terminated NCT04933968 - Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant Phase 1/Phase 2
Not yet recruiting NCT04298060 - DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19) Phase 2
Completed NCT01049490 - Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination Device N/A
Completed NCT02367885 - Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants Phase 1/Phase 2
Completed NCT02313155 - Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults Phase 1/Phase 2
Completed NCT00812448 - Catechin Containing Mask for the Prevention of Influenza Infection N/A
Active, not recruiting NCT05818124 - Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated With Experimental Influenza Virus (MK-4482-019) Phase 1
Terminated NCT01160237 - Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM Phase 3
Completed NCT03814720 - Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults Phase 1